Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Oscar KrijgsmanKristel KemperJulia BoshuizenDavid W VredevoogdElisa A RozemanSofia Ibanez MoleroBeaunelle de BruijnPaulien Cornelissen-SteijgerAida ShahrabiMartin Del Castillo Velasco-HerreraJi-Ying SongMaarten A LigtenbergRoelof J C KluinThomas KuilmanPetra Ross-MacDonaldJohn B A G HaanenDavid J AdamsChristian U BlankDaniel S PeeperPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These signatures may be exploited to distinguish melanoma patients who need combination ICB blockade from those who likely benefit from either monotherapy.